Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy

Cancer Science

Volumn 100, Issue 6, 2009, Pages 1047-1050

  Fujita, Kazutoshi ^a   Nakayama, Masashi ^a   Nakai, Yasutomo ^a   Takayama, Hitoshi ^a   Nishimura, Kazuo ^a   Ujike, Takeshi ^b   Nishimura, Kensaku ^b   Aozasa, Katsuyuki ^a   Okuyama, Akihiko ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BIOCHEMISTRY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; GENE CLUSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; AGED; ANALYSIS OF VARIANCE; DISEASE COURSE; LYMPH NODE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROBABILITY; PROSTATE TUMOR; RECURRENT DISEASE;

AGED; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 67649889370     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01146.x     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002, 167:528-34.
3. Sandler HM, Eisenberger MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol 2007, 178:S20-4.
4. Akduman B, Crawford ED. The management of high risk prostate cancer. J Urol 2003, 169:1993-8.
5. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006, 6:659-70.
6. Kosaka Y, Mimori K, Fukagawa T. Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-1 overexpression in peripheral blood. Br J Cancer 2007, 96:1723-8.
7. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005, 9:777-94.
8. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-60.
9. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002, 2:573-83.
10. Stacker SA, Caesar C, Baldwin ME. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-91.
11. Skobe M, Hawighorst T, Jackson DG. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-8.
12. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109:1010-17.
13. Strohmeyer D, Rossing C, Bauerfeind A. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000, 45:216-24.
14. Stearns ME, Wang M, Hu Y, Kim G, Garcia FU. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t (Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest 2004, 84:785-95.
15. Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005, 65:110-16.
16. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol 2000, 164:506-10.
17. Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, de Torres I. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006, 21:857-65.
18. Ferrer FA, Miller LJ, Lindquist R. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999, 54:567-72.
19. Zeng Y, Opeskin K, Goad J, Williams ED. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 2006, 66:9566-75.
20. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005, 201:1089-99.
21. Fischer C, Jonckx B, Mazzone M. Anti-PlGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-75.
22. Cursiefen C, Chen L, Borges LP. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004, 113:1040-50.
23. Murakami M, Zheng Y, Hirashima M. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler Thromb Vasc Biol 2008, 28:658-64.
24. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2002, 2:826-35.
25. Kaplan RN, Riba RD, Zacharoulis S. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-7.